• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PAB 0.00% 0.3¢

PATRYS LIMITED

Patrys Limited is an Australia-based company, which is focused on the development of its... Patrys Limited is an Australia-based company, which is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. The Company's deoxymab platform is based on the deoxymab 3E10 antibody that was identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus. It has developed two humanized forms of deoxymab 3E10, both of which have improved activity over the original deoxymab 3E10 antibody: PAT-DX1, which is a dimer (two joined subunits) of the short chain from the binding domain of deoxymab 3E10, and PAT-DX3, which is a full-sized Immunoglobulin G antibody. Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumors. Its PAT-DX1- nanoparticles (NP) pipeline involves using its PAT-DX1 to develop a new drug based on the targeted delivery of NP carrying therapeutic payloads to the inside of cancer cells.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
PAB 30/10/24 4 1.4K
30/10/24 Last post  sharebroker1 Comments Created with Sketch.  4  Views Created with Sketch.  1.4K 
PAB 30/10/24 78 28K
30/10/24 Last post  JonesingPanda Comments Created with Sketch.  78  Views Created with Sketch.  28K 
PAB 21/10/24 0 291
TRENDING NEWS

React to US elections with Plus500!

NEWS
05 Nov 2024
21/10/24 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  291 
PAB 14/10/24 0 384
14/10/24 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  384 
PAB 30/09/24 26 8.5K
30/09/24 Last post  Cornhulio Comments Created with Sketch.  26  Views Created with Sketch.  8.5K 
PAB 20/09/24 56 19K
20/09/24 Last post  Travis Cloke Comments Created with Sketch.  56  Views Created with Sketch.  19K 
PAB 28/08/24 103 31K
28/08/24 Last post  Travis Cloke Comments Created with Sketch.  103  Views Created with Sketch.  31K 
PAB 24/08/24 4 1.9K
24/08/24 Last post  Thejerry01 Comments Created with Sketch.  4  Views Created with Sketch.  1.9K 

See All Discussions arrow Created with Sketch.

Timeline

Appendix 4C - Quarterly - 30 September 2024
30 Oct 08:57
 
Notice of Annual General Meeting/Proxy Form
21 Oct 09:40
 
Notification of cessation of securities - PAB
14 Oct 17:00
 
PAT-DX1 clinical development update
02 Oct 08:54
 
PAT-DX1 GMP specification testing update
20 Sep 09:16
 
PAT-DX1 GMP specification testing update
29 Aug 09:15
 
View More arrow Created with Sketch.
(20min delay)
Last
0.3¢
Change
0.000(0.00%)
Mkt cap ! $6.172M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
35 40042144 0.3¢
 

Sellers (Offers)

Price($) Vol. No.
0.4¢ 10681500 13
View Market Depth
Last trade - 16.12pm 05/11/2024 (20 minute delay) ?
Last
0.3¢
  Change
0.000 ( 0.00 %)
Open High Low Volume
0.3¢ 0.3¢ 0.3¢ 235700
Last updated 13.21pm 05/11/2024 ?
PAB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.